Search hospitals > Alaska > Anchorage
Alaska Oncology and Hematology LLC
Claim this profileAnchorage, Alaska 99508
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
210 reported clinical trials
8 medical researchers
Summary
Alaska Oncology and Hematology LLC is a medical facility located in Anchorage, Alaska. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Alaska Oncology and Hematology LLC is involved with conducting 210 clinical trials across 412 conditions. There are 8 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Nitya Alluri, and Krishna C. Alluri.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Alison K. ConlinProvidence Portland Medical Center4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
101 reported clinical trials
178 drugs studied
Charles W. DrescherProvidence Portland Medical Center7 years of reported clinical research
Expert in Cancer
Studies Tumors
46 reported clinical trials
87 drugs studied
Nitya AlluriProvidence Portland Medical Center1 year of reported clinical research
Expert in Cancer
Studies Recurrence
28 reported clinical trials
79 drugs studied
Krishna C. AlluriProvidence Portland Medical Center4 years of reported clinical research
Expert in Cancer
Studies Adenocarcinoma
26 reported clinical trials
63 drugs studied
Clinical Trials running at Alaska Oncology and Hematology LLC
Breast Cancer
Non-Small Cell Lung Cancer
Cancer
Lung Cancer
Bladder Cancer
Pancreatic Cancer
Bladder Carcinoma
Multiple Myeloma
Gastric Cancer
Prostate Cancer
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
Recruiting4 awards Phase 3
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
This trial compares the effectiveness of a combination of two drugs, SG and pembrolizumab, in patients with advanced triple-negative breast cancer. SG targets and kills cancer cells with chemotherapy, while pembrolizumab helps the immune system attack the cancer. Pembrolizumab has been shown to improve survival in various cancers, including triple-negative breast cancer, when used alone or in combination with other treatments.
Recruiting4 awards Phase 3
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Alaska Oncology and Hematology LLC?
Alaska Oncology and Hematology LLC is a medical facility located in Anchorage, Alaska. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Alaska Oncology and Hematology LLC is involved with conducting 210 clinical trials across 412 conditions. There are 8 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Nitya Alluri, and Krishna C. Alluri.